EP0514193A1 — N-linked imidazolyl-methyl benzofuran derivatives with antihypotensive activity
Assigned to Glaxo Group Ltd · Expires 1992-11-19 · 33y expired
What this patent protects
The invention provides compounds of the general formula (I): or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein R¹ represents a hydrogen atom or a halogen atom or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, fluoroC₁₋₆alkyl, C₁…
USPTO Abstract
The invention provides compounds of the general formula (I): or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein R¹ represents a hydrogen atom or a halogen atom or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, fluoroC₁₋₆alkyl, C₁₋₆alkoxy -CHO, -CO₂H or -COR²; Ar represents the group R² represents a group selected from C₁₋₆alkyl, C₂₋₆alkenyl,C₁₋₆alkoxy or the group -NR¹⁰R¹¹; R³ represents a group selected from -SO₃R¹⁵, -PO(OR¹⁵)₂, -PO(OR¹⁶)R¹⁶, -SO₂NHR¹⁶, -CONHOR¹⁶, -CONHNHSO₂CF₃, -SO₂NH- heteroaryl, -CH₂SO₂NH-heteroaryl, -SO₂NHCOR¹⁷, -CH₂SO₂NHCOR¹⁷, -CONHSO₂R¹⁷,-CH₂CONHSO₂R¹⁷, -NHSO₂NHCOR¹⁷, -NHCONHSO₂R¹⁷. -SO₂NHCONHR¹⁷, -CONHSO₂NHR¹⁷, R⁴ and R⁵ which may be the same or different each independently represent a hydrogen atom or a halogen atom or a C₁₋₆ alkyl group; Het represents an N-linked imidazolyl group optionally substituted by one, two or three substituents; R¹⁰ and R¹¹, which may be the same or different, each independently represent a hydrogen atom or a C₁₋₄alkyl group or -NR¹⁰R¹¹ forms a saturated heterocyclic ring which has 5 or 6 ring members and may optionally contain in the ring one oxygen atom; and R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, and R²² are a variety ofsubstituents and groups; m represents an integer from 1 to 4, preferably 1 or 2, especially 1; n represents an integer from 0 to 4, preferably 0, 1 or 2, especially 0 or 1; and p represents an integer from 1 to 4, preferably 1 or 2. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
Drugs covered by this patent
- Venclexta (venetoclax) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.